Skip to main content

Table 1 Baseline characteristics of patients

From: How to manage synchronous endometrial and ovarian cancer patients?

Variables Total (N = 47) DP (N = 28) Meta (N = 19) P-value
Age (med, min-max) 52 (24–70) 50 (24–69) 54 (39–70) 0.263
Approach     1.000
 Laparoscopy 9 (19.1) 5 (17.9) 4 (21.1)  
 Laparotomy 38 (80.9) 23 (82.1) 15 (78.9)  
PLND     0.685
 No 7 (14.9) 5 (17.9) 2 (10.5)  
 Yes 40 (85.1) 23 (82.1) 17 (89.5)  
PALND     1.000
 No 12 (25.5) 7 (25.0) 5 (26.3)  
 Yes 35 (74.5) 21 (75.0) 14 (73.7)  
LVS I     0.417
 No 40 (85.1) 25 (89.3) 15 (78.9)  
 Yes 7 (14.9) 3 (10.7) 4 (21.1)  
Endocervix-invasion     0.381
 No 42 (89.4) 26 (92.9) 16 (84.2)  
 Yes 5 (10.6) 2 (7.1) 3 (15.8)  
Pelvic_peritoneum_invasion     0.485
 No 36 (76.6) 20 (71.4) 16 (84.2)  
 Yes 11 (23.4) 8 (28.6) 3 (15.8)  
Endometrial FIGO stage     <.001
 1 30 (63.8) 24 (85.8) 6 (31.6)  
 2 2 (4.3) 2 (7.1) 0 (0.0)  
 3 12 (25.5) 2 (7.1) 10 (52.6)  
 4 3 (6.4) 0 (0.0) 3 (15.8)  
Ovarian FIGO stage miss = 12    0.038
 1 19 (54.2) 16 (57.1) 3 (42.9)  
 2 8 (22.9) 8 (28.6) 0 (0.0)  
 3 7 (20.0) 4 (14.3) 3 (42.9)  
 4 1 (2.9) 0 (0.0) 1 (14.2)  
Endometrial histology     0.018
 Non-endometrioid 11 (23.4) 3 (10.7)
2 serous
1 clear cell
8 (42.1)
5 serous
1 clear
1 mixed
1 carcinosarcoma
 
 Endometrioid 36 (76.6) 25 (89.3) 11 (57.9)  
Ovarian histology     0.210
 Non-endometrioid 22 (46.8) 11 (39.3)
5 serous
2 clear
2 seromucinous
1 mucinous
1 carcinosarcoma
11 (57.9)
8 serous
2 mixed
1 carcinosarcoma
 
 Endometrioid 25 (53.2) 17 (60.7) 8 (42.1)  
Endometrial FIGO grade miss = 8    0.002
 1 17 (43.6) 16 (61.5) 1 (7.7)  
 2 11 (28.2) 6 (23.1) 5 (38.5)  
 3 11 (28.2) 4 (15.4) 7 (53.8)  
Ovarian grade miss = 7    0.056
 1 15 (37.5) 13 (50.0) 2 (14.3)  
 2 13 (32.5) 8 (30.8) 5 (35.7)  
 3 12 (30.0) 5 (19.2) 7 (50.0)  
Adjuvant chemotherapy     0.685
 No 7 (14.9) 5 (17.9) 2 (10.5)  
 Yes 40 (85.1) 23 (82.1) 17 (89.5)  
Adjuvant radiotherapy     1.000
 No 42 (89.4) 25 (89.3) 17 (89.5)  
 Yes 5 (10.6) 3 (10.7) 2 (10.5)  
  1. DP Double primary, PALND Para-aortic lymph node dissection, PLND Pelvic lymph node dissection